
UNC Researchers Identify a New HIV Reservoir
Findings reveal a second target for cure research. Jenny Honeycutt, PhD, a postdoctoral research associate in the division of infectious diseases, is the study's lead author.
Findings reveal a second target for cure research. Jenny Honeycutt, PhD, a postdoctoral research associate in the division of infectious diseases, is the study's lead author.
UNC researcher Jessica Y. Islam, in collaboration with the National Cancer Institute and Centers for Disease Control and Prevention, reported findings today at the American Association for Cancer Research Annual Meeting that the total number of HIV-positive cancer patients in the United States is projected to decrease through 2030. Researchers project that there will be a decrease in cancers linked to the advanced stage of HIV infection -- AIDS.
By blocking a specific cell signaling pathway in lab animals, researchers reversed signs of chronic immune activation, thereby boosting T-cell recovery and viral suppression.
Robert Hill has been living with HIV for 22 years. Five years ago, he enrolled in a study at the UNC School of Medicine, which was part of Dr. David Margolis’ ‘kick and kill’ strategy for eradicating HIV by flushing it out of hiding with a drug called Vorinostat and killing it with either a vaccine
In honor of World AIDS Day on Dec. 1, we take a look at the trailblazing ‘kick and kill’ method of attacking HIV to cure patients. UNC researchers have been working with GlaxoSmithKline on parallel studies at the UNC Cure Center for 18 months to advance this new method of combating the global epidemic of HIV.
The study published in The Lancet showed no therapeutic benefit of empiric TB therapy for patients with HIV.